2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1302

Early Neutropenia Is Associated with Clinical Response in Patients Receiving Tocilizumab in Rheumatoid Arthritis
Abstract Number: 2144

Early RA Patients Fulfilling the New 2010 ACR/EULAR Criteria, Display Better Clinical Responses to DMARD Therapy but Have Higher Radiographic Damage Progression Than Patients with Early RA Not Fulfilling the 2010 ACR/EULAR Criteria
Abstract Number: 1691

Early Signs of Subclinical Inflammation and Local Antibody Production in Early Rheumatoid Lungs
Abstract Number: 1836

Early Versus Delayed Initiation of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Abstract Number: 1479

Early Versus Late Onset Systemic Sclerosis: Analysis of 1037 Patients From Rescle Registry
Abstract Number: 506

Ebv-Mir-Bart13 Affects the Expression of AQP5 in Human Salivary Gland Cell Lines Contributing to the Pathogenesis of Sjögren’s Syndrome
Abstract Number: 933

Economic Burden of Systemic Lupus Erythematosus by Flare Severity in a Commercially Insured Population in the United States
Abstract Number: 1973

Effect of Adalimumab On the Serum Level of Undercarboxylated Osteocalcin (ucOC), Bone Biochemical Markers and Bone Mineral Density
Abstract Number: 261

Effect of Advancing Age On the Gastrointestinal Safety of Celecoxib Versus Nonselective Nonsteroidal Anti-Inflammatory Drugs: A Post Hoc Analysis of GI-Reasons
Abstract Number: 1080

Effect of Anti-NKG2A Antibody Treatment On NK Cell Receptor Expression in Rheumatoid Arthritis Patients
Abstract Number: 756

Effect of B Cell Depletion Therapy with Rituximab On Myositis Associated Autoantibody Levels in Idiopathic Inflammatory Myopathy
Abstract Number: 1705

Effect of Certolizumab Pegol On Inflammation of Spine and Sacroiliac Joints in Patients with Axial Spondyloarthritis: 12 Week Magnetic Resonance Imaging results of a Phase 3 Double Blind Randomized Placebo-Controlled Study
Abstract Number: 2613

Effect of Certolizumab Pegol On Signs and Symptoms in Patients with Psoriatic Arthritis with and without Prior Anti-TNF Exposure: 24 Week Results of a Phase 3 Double-Blind Randomized Placebo-Controlled Study
Abstract Number: 777

Effect of Certolizumab Pegol On Signs and Symptoms of Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 24 Week Results of a Double Blind Randomized Placebo-Controlled Phase 3 Axial Spondyloarthritis Study
Abstract Number: 557

Effect of Certolizumab Pegol On the Multiple Facets of Psoriatic Arthritis As Reported by Patients: 24 Week Patient Reported Outcome Results of a Phase 3 Double Blind Randomized Placebo-Controlled Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].